InnoCare Pharma Receives FDA Approval for Mesutoclax in Myeloid Malignancies
Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) announced that it has received clinical trial...
July 2025
Pfizer and Astellas’ Xtandi Shows Positive Results in Phase III EMBARK Study for Prostate Cancer
Partners Pfizer (NYSE: PFE) and Astellas Pharma Inc. (TYO: 4503) announced positive topline results from...
Bayer’s Elinzanetant Granted UK Marketing Authorization for Menopause-Related Vasomotor Symptoms
Germany’s Bayer (ETR: BAYN) this week announced that the UK Medicines and Healthcare products Regulatory...
AbbVie Licenses IGI Therapeutics’ ISB 2001 for Oncology and Autoimmune Diseases
US-based AbbVie (NYSE: ABBV) this week announced a licensing agreement with IGI Therapeutics SA, a...
Jiangsu Jibeier Receives NMPA Approval for Clinical Trials of JJH201601 Liposome in Advanced HNSCC
China-based Jiangsu Jibeier Pharm Co., Ltd (SHA: 688566) announced that it has received clinical approval...
Fosun Pharmaceutical Launches Phase III Study for Fumaining in Pediatric Low-Grade Glioma
Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced the initiation of a...
BeOne Medicines’ Tevimbra Approved by European Commission for Nasopharyngeal Carcinoma
China-based BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced that it has received...
Johnson & Johnson MedTech Launches VARIPULSE Platform for Atrial Fibrillation in Asia-Pacific
US major Johnson & Johnson MedTech announced the launch of its VARIPULSE Platform in the...
JCR Pharmaceuticals Signs Licensing Agreement with AstraZeneca’s Alexion for JUST-AAV Gene Therapy Platform
Japan-based JCR Pharmaceuticals Co., Ltd. (TYO: 4552) announced a licensing agreement with UK-based AstraZeneca’s (NASDAQ:...
Zhimeng Biopharma’s CB03-154 Receives CDE Approval for ALS Phase II/III Clinical Study
China-based Shanghai Zhimeng Biopharma, Inc. is set to carry out a Phase II/III clinical study...
NHSA Finalizes 2025 Drug Catalog Adjustment Plan with Minimal Changes from Draft
The National Healthcare Security Administration (NHSA) this week issued the finalized “2025 National Basic Medical...
MSD’s Once-Daily HIV-1 Therapy Doravirine/Islatravir NDA Accepted by FDA for Review
Merck, Sharp & Dohme (MSD, NYSE: MRK) announced that the U.S. Food and Drug Administration...
Zelgen’s ZG006 Receives Breakthrough Therapy Designation for Advanced Small Cell Lung Cancer
China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that it has received breakthrough therapy...
Cosunter’s GST-HG131 Granted Breakthrough Therapy Designation for HBV Treatment in China
China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) announced that it has received breakthrough therapy...
Ascentage Pharma’s Lisaftoclax Receives NMPA Approval for CLL/SLL Treatment
China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) announced that it has received conditional marketing approval...
Allist’s Furmonertinib Granted Priority Review for EGFR Exon 20 NSCLC in China
Shanghai-based biotech Allist Pharmaceuticals Co., Ltd. (SHA: 688578) announced that its Category 1 small molecule...
HKYM Biopharma’s KM1 Receives NMPA Green-Light for Phase Ib/II Study in Advanced Solid Tumors
Shenzhen-based oncolytic virus specialist HKYM Biopharma has announced receiving the green-light from the National Medical...
United Laboratories Receives FDA Approval for Clinical Study of UBT37034 in Overweight/Obesity Treatment
Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) has announced that it has received...
CStone Pharmaceuticals Receives NMPA Approval for Local Production of Gavreto in China
China-based CStone Pharmaceuticals (HKG: 2616) has announced that it has received approval from the National...
Biocytogen and BeOne Medicines Deepen Partnership with Global Antibody Licensing Agreement
China’s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) has announced a global antibody molecule licensing...